Podcast

At-Home Genetic Testing: Dispelling Fact vs Fiction

Author(s):

Kristie L. Kahl

This week, we spoke with FORCE to dispel some of the misconceptions associated with at-home genetic testing for hereditary cancer risk.

With the flood of information available on genetic testing for hereditary cancer risk, there is still an abundance of misinformation that exists regarding at-home tests.

Lisa Schlager, Vice President of Community Affairs and Public Policy at FORCE, helped to dispel some of the misconceptions associated with at-home genetic testing, and why it is still vital to include a genetic counselor in this process.

For more information, visit www.facingourrisk.org.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Image of woman.
Sue Friedman in an interview with CURE
Dr. Alex Francoeur interviewing against a gray CURE background
Related Content
INX-315 received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian cancer: © stock.adobe.com.
April 29th 2025

FDA Fast Tracks INX-315 for Tough-to-Treat Ovarian Cancer

Spencer Feldman
INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian cancer.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of ovaries.
April 3rd 2025

Development of Nemvaleukin for Platinum-Resistant Ovarian Cancer Halted

Alex Biese
A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on to final analysis.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Illustration of ovaries.
March 24th 2025

First Patient Dosed in Phase 3 Trial of IBI354 for Ovarian Cancer

Spencer Feldman
The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.
The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized: © Tada Images - stock.adobe.com
March 24th 2025

Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer

Alex Biese
The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory agencies.